SYDNEY Australia, Thursday, 4 June 2020 – Atomo Diagnostics...

SYDNEY Australia, Thursday, 4 June 2020 – Atomo Diagnostics Limited (ASX: AT1)

(Atomo) is pleased to announce it has expanded its existing COVID-19 rapid test

partnership with NG Biotech, SAS (NG Biotech), which was announced to ASX on 14 April

2020 in Atomo’s Second Supplementary Prospectus (Second Supplementary

Prospectus).

Under Atomo’s existing binding supply agreement with NG Biotech referenced in the Second

Supplementary Prospectus, Atomo has been supplying NG Biotech with its award-winning

Galileo rapid test device for use in NG Biotech’s blood-based rapid antibody IgG/IgM

COVID19 test (the COVID-19 antibody test) which is branded ‘NG Test IgG / IgM

COVID19’ when sold by NG Biotech in Europe. To date, NG Biotech has ordered in excess

of 1.5 million Galileo devices from Atomo for use in NG Biotech’s COVID-19 antibody test in

France.

Under the expansion of the Atomo NG Biotech partnership, Atomo now has exclusive rights

to market and distribute, as the listed manufacturer, the COVID-19 antibody test in Australia

and New Zealand and a number of countries in South East Asia1

, subject to obtaining the

required regulatory approvals in each jurisdiction, under the brand ‘AtomoRapidTM COVID-19

(IgG/IgM)’. At present, the period of exclusivity has not been specified (ie. it is not currently

limited) and Atomo and NG Biotech are continuing to negotiate a definitive long term supply

agreement. The pricing arrangements with NG Biotech are limited to a price payable per unit

only and do not include any licence fees or royalties.

The exclusive rights arrangement for Australia, New Zealand and a number of South-East

Asian countries is strategically important for Atomo as it repositions Atomo as a listed

manufacturer of COVID-19 tests, building on its foundation of being the only manufacturer of